The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of olaparib tablets (Lynparza) as a maintenance therapy for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
David G. Mutch, MD, discusses questions surrounding the role of radiation therapy for patients with high-risk endometrial cancer.
Standard cisplatin-based concomitant chemoradiation induced superior disease-free survival compared with neoadjuvant chemotherapy followed by radical surgery in women with locally advanced squamous cervical cancer.
Several phase III studies are exploring immunotherapy combinations with the potential to disrupt the systemic treatment paradigm for patients with ovarian cancer.
PARP inhibitor combination regimens have the potential to enhance the relatively modest benefit offered by several monotherapy approaches used for the treatment of patients with ovarian cancer.
Rebecca C. Arend, MD, discussed novel combinations being investigated for the treatment of patients with ovarian cancer.
David O'Malley, MD, discusses the excitement surrounding PARP inhibitors for patients with ovarian cancer.
Many endometrioid cancers express high RNA levels for multiple immune checkpoints, and this may allow physicians to treat these patients with combination immune therapies.
Kathleen Moore, MD, discusses combination strategies with immunotherapy for patients with ovarian cancer.
An analysis of black women of Caribbean descent with type I or type II endometrial cancer showed that this population expressed significant differences in genetic variations compared with a nationwide population of patients with endometrial cancer.